Shares of Myriad Genetics MYGN moved higher by 1.64% in after-market trading after the company reported Q4 results.
Earnings per share fell 175.61% year over year to ($0.31), which beat the estimate of ($0.47).
Revenue of $93,200,000 declined by 56.73% year over year, which missed the estimate of $93,850,000.
Myriad Genetics hasn't issued any earnings guidance for the time being.
Myriad Genetics hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 13, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/6w3d9td9
Recent Stock Performance
52-week high: $47.10
Company's 52-week low was at $9.24
Price action over last quarter: down 5.97%
Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.